<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Treatment of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> by activation of endogenous plasminogen using tissue plasminogen activator is limited by <z:mp ids='MP_0001914'>bleeding</z:mp> side effects </plain></SENT>
<SENT sid="1" pm="."><plain>In mice, treatment of experimental <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> with activated protein C improves outcomes; however, activated protein C also has <z:mp ids='MP_0001914'>bleeding</z:mp> side effects </plain></SENT>
<SENT sid="2" pm="."><plain>In contrast, activation of endogenous protein C using thrombin mutant W215A/E217A (WE) is antithrombotic without hemostasis impairment in primates </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, we investigated the outcome of WE-treated experimental <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> in mice </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: The middle cerebral artery was occluded with a filament for 60 minutes to induce <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Vehicle, recombinant WE, or tissue plasminogen activator was administered during middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> or 2 hours after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>Neurological performance was scored daily </plain></SENT>
<SENT sid="7" pm="."><plain><z:mp ids='MP_0001915'>Intracranial bleeding</z:mp> and cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> size, defined by 2,3,5-triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> exclusion, were determined on autopsy </plain></SENT>
<SENT sid="8" pm="."><plain>Hemostasis was evaluated using tail <z:mp ids='MP_0001914'>bleeding</z:mp> tests </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: WE improved neurological performance scores, increased laser Doppler flowmetry-monitored post-middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> reperfusion of the parietal cortex, and reduced 2,3,5-triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi>-defined cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> size versus vehicle controls </plain></SENT>
<SENT sid="10" pm="."><plain>However, unlike tissue plasminogen activator, WE did not increase tail <z:mp ids='MP_0001914'>bleeding</z:mp> or <z:hpo ids='HP_0002170'>intracranial hemorrhage</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: WE treatment is neuroprotective without hemostasis impairment in experimental <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> in mice and thus may provide an alternative to tissue plasminogen activator for <z:hpo ids='HP_0001297'>stroke</z:hpo> treatment </plain></SENT>
</text></document>